Puma Biotechnology Inc PBYI:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 2:51 PM EDT
11.40quote price arrow down-0.20 (-1.72%)
Volume
156,103
52 week range
7.48 - 14.14

...

Loading . . .
  • Open11.58
  • Day High11.73
  • Day Low11.35
  • Prev Close11.60
  • 52 Week High14.14
  • 52 Week High Date02/10/21
  • 52 Week Low7.48
  • 52 Week Low Date11/06/20

Key Stats

  • Market Cap460.10M
  • Shares Out40.36M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change12.09

KEY STATS

  • Open11.58
  • Day High11.73
  • Day Low11.35
  • Prev Close11.60
  • 52 Week High14.14
  • 52 Week High Date02/10/21
  • 52 Week Low7.48
  • 52 Week Low Date11/06/20
  • Market Cap460.10M
  • Shares Out40.36M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change12.09

RATIOS/PROFITABILITY

  • EPS (TTM)-0.68
  • P/E (TTM)-16.78
  • Fwd P/E (NTM)-24.20
  • EBITDA (MRQ)15.063M
  • ROE (MRQ)-205.58%
  • Revenue (MRQ)272.06M
  • Gross Margin (MRQ)78.00%
  • Net Margin (MRQ)-9.75%
  • Debt To Equity (MRQ)603.53%

EVENTS

  • Earnings Date08/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Puma Biotechnology Inc

There is no recent news for this security.

Profile

MORE
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor...
Alan Auerbach
Chairman
Maximo Nougues
Chief Financial Officer
Address
10880 Wilshire Blvd Ste 2150
Los Angeles, CA
90024-4106
United States

Top Peers

SYMBOLLASTCHG%CHG
AKBA
Akebia Therapeutics Inc
3.66-0.01-0.41%
ICPT
Intercept Pharmaceuticals Inc
21.78+0.38+1.78%
OVID
Ovid Therapeutics Inc
4.48+0.04+0.90%
TVTX
Travere Therapeutics Inc
14.56-0.31-2.12%
CLVS
Clovis Oncology Inc
6.01-0.29-4.68%